Neoadjuvant chemoradiotherapy plus tislelizumab followed by surgery for esophageal carcinoma (CRISEC study): the protocol of a prospective, single-arm, phase II trial

Neoadjuvant chemoradiotherapy plus tislelizumab followed by surgery for esophageal carcinoma (CRISEC study): the protocol of a prospective, single-arm, phase II trial

Abstract Background The failure rate after neoadjuvant chemoradiotherapy followed by surgery is approximately 34.6%–48% for resectable esophageal carcinoma. Pathologic complete response after neoadjuvant chemoradiotherapy is an important factor in predicting lower recurrence and better survival. Whe...

Full description

Bibliographic Details
Main Authors: Jinsong Yang, Ai Huang, Kunyu Yang, Ke Jiang
Format: Article
Language:English
Published: BMC 2023-03-01
Series:BMC Cancer
Subjects:
Esophageal carcinoma
Neoadjuvant
Chemoradiotherapy
Immunotherapy
Tislelizumab
Surgery
Online Access:https://doi.org/10.1186/s12885-023-10687-8

Similar Items

Similar Items